What is invasive disease‑free survival (IDFS) and how is it used as an endpoint in oncology clinical trials?

Invasive Disease-Free Survival (IDFS): Definition and Use in Oncology Trials

Invasive disease-free survival (iDFS) is a standardized time-to-event endpoint measuring the time from randomization until invasive breast cancer recurrence (ipsilateral, locoregional, or distant), contralateral invasive breast cancer, or death from any cause—specifically excluding non-invasive disease and second primary non-breast cancers. 1

Standardized Definition

The DATECAN initiative established iDFS through formal international consensus to address the ambiguity of traditional "disease-free survival" (DFS), which experts deemed too vague for breast cancer trials. 1 The endpoint was specifically designed for non-metastatic breast cancer settings. 1

Events Included in iDFS:

• Invasive ipsilateral breast tumor recurrence 1
• Local invasive recurrence/progression 1
• Regional invasive recurrence/progression 1
• Invasive contralateral breast cancer 1
• Appearance/occurrence of distant metastases 1
• Death from any cause 1

Events Explicitly Excluded:

• Ipsilateral or contralateral ductal carcinoma in situ (DCIS) 1
• Second primary invasive non-breast cancers 1

The reference date is typically randomization, though it may be diagnosis or treatment initiation depending on study design. 1

Clinical Application in Trials

Primary Endpoint Use

iDFS has become the preferred primary endpoint in adjuvant breast cancer trials, particularly for HER2-positive and hormone receptor-positive disease. 1 The APHINITY trial (pertuzumab in HER2+ breast cancer) defined iDFS as "time from randomization until the date of the first occurrence of recurrence of ipsilateral invasive breast tumor, recurrence of ipsilateral locoregional invasive disease, distant disease recurrence, contralateral invasive breast cancer, or death from any cause." 1

Recent adjuvant CDK4/6 inhibitor trials (monarchE with abemaciclib and NATALEE with ribociclib) both used iDFS as their primary endpoint and demonstrated statistically significant improvements. 1

Rationale for Use Over Overall Survival

In early breast cancer, overall survival (OS) requires prohibitively long follow-up due to improved treatments and longer expected survival. 1 Many other endpoints have been adopted to accelerate drug development, but lack of consistency between definitions has complicated cross-trial comparisons and meta-analyses. 1

The standardization of iDFS enables:

• Consistent interpretation of trial results across studies 1
• Facilitation of cross-trial comparisons and meta-analyses 1
• Shorter trial duration compared to OS 1
• Objective and clinically meaningful assessment 2

Critical Limitations and Controversies

Lack of Validation as OS Surrogate

iDFS has NOT been validated as a surrogate for overall survival in hormone receptor-positive early breast cancer. 1 This represents a fundamental limitation, as the primary goal of adjuvant therapy is to improve cure rates, not merely delay recurrence. 1

The composite nature of iDFS means it can be influenced by:

• Trial design choices regarding event definitions 1
• Frequency of patient monitoring 1
• Reasons for treatment discontinuation and censoring rules 1
• Duration of follow-up 1

Real-World Correlation Data

A 2025 real-world analysis of 3,133 patients with HR+/HER2- early breast cancer demonstrated very strong correlation between iDFS and OS (Spearman ρ: 0.88; R² = 0.82), with iDFS accounting for 82% of variation in OS. 2 However, this observational data does not establish iDFS as a validated surrogate endpoint for treatment effect on OS.

Clinical Context Matters

In settings where the vast majority of patients are already cured with standard therapy and effective treatments exist at recurrence, gains in iDFS alone may not reflect meaningful or lasting benefit. 1 The monarchE and NATALEE trials both showed iDFS improvements but neither demonstrated statistically significant OS benefit (monarchE: HR 0.903,95% CI 0.749-1.088, p=0.284; NATALEE: HR 0.76,95% CI 0.54-1.07). 1

Common Pitfalls to Avoid

Inconsistent Event Definitions

The same endpoint name can encompass different event sets across trials, leading to misinterpretation. 1 For example, some trials include second primary non-breast cancers in their "DFS" definition while others exclude them. 1 Always verify the specific events included in each trial's endpoint definition.

Confusion with Related Endpoints

Do not confuse iDFS with:

• Disease-free survival (DFS): May include non-invasive disease 1
• Invasive breast cancer-free survival (IBCFS): A newer STEEP 2021 endpoint that specifically excludes second primary non-breast cancers and requires careful consideration of how these events are handled statistically 3
• Distant disease-free survival (D-DFS): Only includes distant recurrence and death 1
• Recurrence-free survival (RFS): May have different event definitions 1

Lost to Follow-Up

Patients lost to follow-up should NOT be included as events in iDFS and should be censored at the time of last known status. 1

Treatment-Related Deaths

The event "death related to protocol treatment" remains controversial with no consensus reached during DATECAN. 1 Future trials should clearly define this event by specifying all included components. 1